BioSpace News Archive

ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company’s investigational Diabetes Bloc-Stim Neuromodulation™ (DBS

Hemp-derived, non-psychoactive cannabinoid manufacturer Folium Biosciences welcomes Kandy Anand, former Chief Growth Officer at Molson Coors Brewing Company, to its Board of Directors.

CareDx, Inc. announced the appointment of new senior leaders to significantly strengthen key areas of the business - Digital Services, Laboratory Operations, Business Development, and Market Access.

- Investigational New Drug (IND) application was authorized to proceed by the US FDA for human dosing with oral zavegepant - Biohaven achieved first in human dosing with oral zavegepant to assess the safety and pharmacokinetic profile - Zavegepant is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist in development for both migraine and non-migraine indications including COVID-19 associated lung inflammation

The Bausch Foundation (“Foundation”), which oversees and directs the charitable giving efforts of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today released its Inaugural Activity Report , which highlights the

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that its Chairman and Chief Executive Officer Sandesh Seth will be presenting at the virtual H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14 th at 2:00 PM EST .

Pilot program initially launching in Alabama aligns APADAZ with Sure Med’s Care Continuity Program® to collect data and create a more informed opioid prescribing environment

ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hem

Application is based on positive results from the Phase 3 ANDROMEDA study evaluating the efficacy and safety of combination therapy with DARZALEX FASPRO™

Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15 th , 2020 at 12:00 PM ET. The online conference is being held September 14-16, 2020. Dr. Norchi and Mr. Richard Davis, Chief Fi